ACT Capital Management’s Marker Therapeutics MRKR Stock Holding History

ACT Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$131K	Hold	35,440	–	–	0.18%	45
2022 Q2	$117K	Hold	35,440	–	–	0.16%	46
2022 Q1	$156K	Hold	35,440	–	–	0.17%	56
2021 Q4	$337K	Sell	35,440 -8,500	-19%	-$113K	0.24%	55
2021 Q3	$743K	Buy	43,940 +1,940	+5%	+$39.7K	0.39%	46
2021 Q2	$1.17M	Buy	+42,000	New	+$1.11M	0.6%	36

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $546M AUM 24.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

ACT Capital Management's MRKR Position: Q3 2022 in Review

ACT Capital Management held its Marker Therapeutics (MRKR) position steady in Q3 2022 at 35,440 shares worth $131K. The position accounts for 0.18% of the portfolio, ranked #45.

ACT Capital Management first reported a position in MRKR in Q2 2021 and has held it in 6 quarters since. The position peaked at $1.17M in Q2 2021. 45 funds tracked by Wall St. Rank hold MRKR as of Q3 2022.

ACT Capital Management held 35,440 shares of Marker Therapeutics worth $131K as of Q3 2022.
ACT Capital Management left its Marker Therapeutics share count unchanged in Q3 2022.
Marker Therapeutics made up 0.18% of ACT Capital Management's portfolio in Q3 2022, its #45 holding.
ACT Capital Management first reported a position in Marker Therapeutics in Q2 2021 and has held it in 6 quarters since.
ACT Capital Management's Marker Therapeutics position peaked at $1.17M in Q2 2021.
45 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.